Qualification of Biomarker — Galactomannan in studies of treatments of invasive
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 13, 2015
April 15, 2020
609be9e9-d86e-4995-b7df-7b9095d54037
Related Documents
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HBV Resistance Data
Guidance DocumentJune 2, 2006Center for Drug Evaluation and Research
Qualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease Draft Guidance for Industry
Guidance DocumentSeptember 16, 2016Center for Drug Evaluation and Research
Qualification of Biomarker Plasma Fibrinogen in Studies Examining Exacerbations and/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Guidance for Industry
Guidance DocumentSeptember 13, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.